Search filters

List of works by Keith Flaherty

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

article

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

scientific article published in November 2017

A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

scientific article published on 6 March 2018

A Melanoma Molecular Disease Model ⬇️

scientific article (publication date: 30 March 2011)

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

scientific article

A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States)

article by Keith Flaherty et al published November 2005 in Cancer Causes & Control

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

scientific article published on 18 July 2017

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

scientific article published on 3 November 2013

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

scientific article

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

scientific article published on 06 January 2021

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

scientific article published on 25 January 2016

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

scientific article

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

scientific article

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

scientific article

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives

scientific article published in September 2017

Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma

scientific article published on 15 July 2016

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

scientific article published on July 16, 2012

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

scientific article published on 09 March 2017

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

scientific article published on 30 January 2020

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

scientific article published on 08 March 2016

Advances in drug development. BRAF validation in melanoma.

scientific article published in January 2010

Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients

scientific article

Age as a prognostic factor in patients with localized melanoma and regional metastases

scientific article

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

scientific article published on 19 October 2016

An active learning approach for rapid characterization of endothelial cells in human tumors

scientific article

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells

scientific article published in January 2007

Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma

scientific article published on 05 February 2016

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

scientific article published on 12 February 2018

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 19 June 2020

Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

scientific article published on 01 November 2019

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

scientific article published on 12 March 2019

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A

scientific article published on 15 June 2015

BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA.

scientific article published on 9 November 2015

BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape

scientific article

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice ⬇️

scientific article published on November 30, 2012

BRAF Inhibitors and Melanoma ⬇️

scientific article published on November 1, 2011

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance ⬇️

scientific article published on January 1, 2012

BRAF in Melanoma: Current Strategies and Future Directions ⬇️

scientific article published on June 14, 2013

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance ⬇️

scientific article published on November 17, 2011

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

scientific article published on 15 October 2013

BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma

scientific article published on 19 July 2017

BRAF targeted therapy changes the treatment paradigm in melanoma ⬇️

scientific article published on May 24, 2011

BRAF, a target in melanoma: implications for solid tumor drug development

scientific article

Bevacizumab plus ipilimumab in patients with metastatic melanoma

scientific article

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

scientific article published on 8 March 2017

Biological challenges of BRAF inhibitor therapy

scientific article published on 16 February 2011

Biology of advanced uveal melanoma and next steps for clinical therapeutics

scientific article

Biomarkers in Melanoma: Lessons from Translational Medicine

scientific article

Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma

scientific article published on 09 April 2010

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma

scientific article published on July 2007

CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA

CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma ⬇️

scientific article published on April 24, 2013

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation

scientific article published in October 2007

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

scientific article published on 01 September 2019

Chemotherapy and targeted therapy combinations in advanced melanoma

scientific article

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

scientific article published on March 2007

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

scientific article published on 02 August 2013

Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma

scientific article published on September 2008

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

scientific article

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics

scientific article

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma

scientific article

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

scientific article

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma

scientific article published on 12 April 2018

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

scientific article

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

scientific article

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

scientific article

Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series

scientific article published on 31 August 2018

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

scientific article published on 05 October 2020

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

scientific article

Commentary: Molecular testing in melanoma.

scientific article published on 16 February 2014

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, o

article

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics

scientific article

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

scientific article published on 7 October 2015

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib

scientific article

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

scientific article

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma

scientific article published on June 2014

Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma

scientific article published in March 2014

Cyclin-dependent kinases as therapeutic targets in melanoma

scientific article published on 10 February 2014

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

scientific article

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

scientific article published on 01 November 2018

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

scientific article published on 14 November 2019

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment

scientific article

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

scientific article published on 22 February 2018

Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment

scientific article

Discovery and clinical introduction of first-in-class imipridone ONC201.

scientific article published on September 2016

Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials

scientific article published on October 2015

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

scientific article published on April 2016

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

scientific article published on 2 February 2016

Distinct histone modifications denote early stress-induced drug tolerance in cancer

scientific article published on 24 December 2017

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets ⬇️

scientific article published on June 3, 2012

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer

scientific article

Drug targeting of oncogenic pathways in melanoma

scientific article published on June 2009

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib ⬇️

scientific article published on January 16, 2012

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma

scientific article

Effectively targeting CRAF: rational serendipity targeting SRC?

scientific article

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

scientific article

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

scientific article published on 23 May 2016

Elucidating distinct roles for NF1 in melanomagenesis

scientific article

Emerging Strategies in Systemic Therapy for the Treatment of Melanoma

scientific article published on 01 May 2018

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

scientific article

Evolution of delayed resistance to immunotherapy in a melanoma responder

scientific article published on 03 May 2021

Expanded access programmes: patient interests versus clinical trial integrity

scientific article published on 29 December 2014

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel

scientific article (publication date: 2013)

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib

scientific article

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma

scientific article published on June 2006

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

scientific article

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations

scientific article published on 26 April 2017

Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma

scientific article published on 23 May 2015

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

scientific article published on 15 December 2017

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors

scientific article published on 4 October 2017

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

scientific article

From genes to drugs: targeted strategies for melanoma ⬇️

scientific article published on 05 April 2012

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

scientific article published on 26 March 2011

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

scientific article published on 4 July 2012

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

scientific article

Genetic alterations and personalized medicine in melanoma: progress and future prospects

scientific article published on February 2014

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

scientific article published in November 2017

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy

scientific article published on 07 April 2009

Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response

scientific article published in May 2017

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice

scientific article published on 02 April 2019

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

scientific article published on December 2008

HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest

scientific article published on February 2007

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

scientific article published on 17 March 2015

Her-2 targeted therapy: beyond breast cancer and trastuzumab

scientific article

High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come

scientific article published in September 2016

Hyperspectral imaging: A non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor ⬇️

scientific article published on August 15, 2011

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

scientific article published on 08 October 2013

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

scientific article published on July 2008

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

scientific article

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings

scientific article published in November 2017

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

scientific article published on 15 January 2018

Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma

scientific article published on 29 September 2015

Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma

scientific article published on 5 May 2017

Improved overall survival in melanoma with combined dabrafenib and trametinib

scientific article

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

scientific article

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma

scientific article published in October 2017

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

scientific article published on September 2008

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

scientific article published on 21 March 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

scientific article (publication date: 26 August 2010)

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

scientific article

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference

scientific article published on January 2007

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 02 December 2019

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

scientific article published on 25 February 2011

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.

scientific article published on 4 November 2015

Ipilimumab for patients with advanced mucosal melanoma

scientific article

Is It Good or Bad to Find a BRAF Mutation? ⬇️

scientific article published on February 22, 2011

Isolation and molecular characterization of circulating melanoma cells

scientific article

It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology ⬇️

scientific article published on July 18, 2011

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome

scientific article published on September 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

scientific article (publication date: 2015)

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma ⬇️

scientific article published on February 15, 2011

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

scientific article

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

scientific article published on 9 October 2017

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

scientific article published on 13 May 2015

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

scientific article published on 08 August 2016

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

scientific article

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

scientific article

MEK and RAF inhibitors for BRAF-mutated cancers

scientific article published on 12 October 2012

MITF Modulates Therapeutic Resistance through EGFR Signaling

scientific article published on 19 March 2015

Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance ⬇️

scientific article published on December 12, 2011

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma

scientific article

Mechanisms of hypertension associated with BAY 43-9006.

scientific article published on 30 January 2006

Mechanisms of resistance to immune checkpoint inhibitors

scientific article published on 2 January 2018

Meeting report from the 2011 International Melanoma Congress, Tampa, Florida

scientific article published on 9 December 2011

Meeting report from the Third Global Workshop on Melanoma.

scientific article

Meeting report: The future of preclinical mouse models in melanoma treatment is now.

scientific article

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients

scientific article published on 16 July 2015

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

scientific article published in December 2017

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Melanoma in 2017: Moving treatments earlier to move further forwards

scientific article published on 28 November 2017

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

scientific article published on 13 October 2017

Melanoma: New Insights and New Therapies ⬇️

scientific article published on January 5, 2012

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.

scientific article published on 4 June 2015

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

Modifying phase I methodology to facilitate enrolment of molecularly selected patients

scientific article published on 16 January 2013

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

scientific article published on 13 October 2020

Molecular therapeutic approaches to melanoma

scientific article published on 20 February 2010

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

scientific article

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

scientific article

Mutation-driven drug development in melanoma

scientific article published on May 2010

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

scientific article published on 13 April 2016

Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma ⬇️

scientific article published on November 2, 2010

New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances ⬇️

scientific article published on June 13, 2011

New challenges in endpoints for drug development in advanced melanoma

scientific article

New drugs in development for melanoma

scientific article published on November 2015

New molecular targets in melanoma

scientific article published on March 2004

New options and new questions: how to select and sequence therapies for patients with metastatic melanoma

scientific article published on January 2012

New strategies in melanoma: entering the era of combinatorial therapy

scientific article published on 01 June 2015

Next generation therapies change the landscape in melanoma ⬇️

scientific article published on January 1, 2011

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

scientific article published on 16 September 2012

One Hippo and many masters: differential regulation of the Hippo pathway in cancer

scientific article

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

scientific article published on 27 February 2014

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

scientific article

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 12 September 2018

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors

scientific article published on 09 March 2017

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

scientific article published on 14 October 2015

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

scientific article published on 27 September 2017

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

scientific article published on 29 July 2019

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

scientific article

PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression

scientific article published on 17 July 2017

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo

scientific article published on 15 June 2016

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

scientific article published on 15 October 2021

Pathways and therapeutic targets in melanoma

scientific article

Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma

scientific article

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

scientific article

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

scientific article published on 24 September 2013

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

scientific article

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

scientific article

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

scientific article

Phase I trial of combretastatin a-4 phosphate with carboplatin

scientific article

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

scientific article published on 13 January 2004

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer ⬇️

scientific article published on November 16, 2011

Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

scientific article published on 17 June 2015

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

scientific article published on December 2009

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

scientific article

Phase II trial of sorafenib in advanced thyroid cancer

scientific article published on 09 June 2008

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification ⬇️

scientific article published on June 20, 2011

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

scientific article

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results.

scientific article published on 6 May 2014

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

scientific article published on 22 January 2008

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome

scientific article published on 13 November 2020

Precision medicine for cancer with next-generation functional diagnostics

scientific article

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

scientific article

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

scientific article published on 13 August 2015

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database

scientific article

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays

scientific article

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

scientific article published on January 2012

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

scientific article published on March 2012

Resistance to BRAF-targeted therapy in melanoma ⬇️

scientific article published on 02 January 2013

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

scientific article published on 07 August 2020

SARS-CoV-2 viral load is associated with increased disease severity and mortality

scientific article published on 30 October 2020

STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming

scientific article published on 06 April 2022

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

scientific article

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

scientific article published on 20 November 2017

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

scientific article published on July 16, 2012

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

scientific article published on 15 June 2010

Sorafenib in renal cell carcinoma

scientific article published on January 2007

Sorafenib: delivering a targeted drug to the right targets

scientific article published on May 2007

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer

scientific article published on 16 June 2016

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

scientific article published on 31 January 2014

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

scientific article

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

scientific article published on 17 December 2015

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

scientific article

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

scientific article published on 12 April 2015

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma ⬇️

scientific article published on July 31, 2013

Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress ⬇️

scientific article published on December 22, 2010

Targeted Molecular Therapy in Melanoma ⬇️

scientific article published on September 1, 2010

Targeted agents and immunotherapies: optimizing outcomes in melanoma

scientific article

Targeted and immunotherapies in BRAF mutant melanoma - where we are standing and what to expect

scientific article published on 11 July 2020

Targeting Metastatic Melanoma ⬇️

scientific article published on October 27, 2011

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

scientific article published on 03 February 2013

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

scientific article published on 4 April 2016

Targeting the RAS pathway in melanoma

scientific article published on 30 September 2011

The Conundrum of Genetic "Drivers" in Benign Conditions

scientific article published on 07 April 2016

The Cost of Hope: A Candid Roundtable Discussion ⬇️

scientific article published on May 1, 2013

The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth

scientific article published on September 2015

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

scientific article published on 09 February 2015

The MAPK pathway in melanoma

scientific article published on March 2008

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

scientific article published in 2013

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells

scientific article published on 14 October 2010

The future of tyrosine kinase inhibitors: single agent or combination?

scientific article published on May 2008

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity

scientific article published on 16 February 2018

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

scientific article published on October 2013

The state of melanoma: challenges and opportunities

scientific article

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

scientific article

Throwing the kitchen sink at melanoma drug development ⬇️

scientific article published on September 1, 2012

Tissue-Agnostic Drug Development

scientific article published on January 2017

Treatment of growing teratoma syndrome

scientific article published in January 2009

Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial

scientific article published on 05 October 2020

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

scientific article published on 24 October 2017

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

scientific article published on 19 September 2017

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy ⬇️

scientific article published on 06 June 2012

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care

scientific article published on 18 February 2010

Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth ⬇️

scientific article published on June 27, 2013

Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells

scientific article published on 29 January 2013

When are signal transduction targeted therapies acting as immunotherapy?

scientific article

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

scientific article published on March 2009

Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?

scientific article

YAP in MAPK pathway targeted therapy resistance

scientific article

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition

scientific article published on 13 October 2011

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

scientific article published on 4 April 2016

Paulina is supported by:

About Paulina

Help